Great Point Partners LLC

Great Point Partners LLC reported 45 holdings worth US$418M as of Sep 30, 2026 (Form 13F)

As of Sep 30, 2026 · Filed Nov 16, 2026

Great Point Partners LLC reported 45 holdings worth US$418M as of Sep 30, 2026. Largest: Vera Therapeutics, Inc., Vor Biopharma Inc. and Amylyx Pharmaceuticals, Inc. Filed Nov 16, 2026 (Form 13F).

Holdings
45
Value as reported
US$418M

The filing in full

CompanySharesValue as reported% of portfolio
Vera Therapeutics, Inc.809KUS$26.1M6.2%
Vor Biopharma Inc.1.13MUS$21.5M5.1%
Amylyx Pharmaceuticals, Inc.700KUS$20.4M4.9%
Sagimet Biosciences Inc. - Series A1.96MUS$19.4M4.6%
Definium Therapeutics, Inc.509KUS$19.4M4.6%
Ionis Pharmaceuticals, Inc.420KUS$18.8M4.5%
Genmab A/S525KUS$18.7M4.5%
Zura Bio Limited4.08MUS$17M4.1%
LB Pharmaceuticals Inc410KUS$15.8M3.8%
Abivax SA155KUS$15.3M3.7%
Annexon, Inc.3.5MUS$14.8M3.5%
Belite Bio, Inc.75,000US$12.7M3.0%
Eupraxia Pharmaceuticals, Inc.1.2MUS$10.9M2.6%
Nektar Therapeutics175KUS$10.6M2.5%
Climb Bio, Inc.800KUS$9.18M2.2%
AbCellera Biologics Inc.600KUS$8.75M2.1%
Neurogene Inc.300KUS$8.35M2.0%
COMPASS Pathways Plc500KUS$6.22M1.5%
JATT II Acquisition Corp500KUS$5.62M1.3%
Research Alliance Corporation III505KUS$5.47M1.3%
Bright Minds Biosciences Inc.110KUS$5.46M1.3%
Amanat Acquisition Corp500KUS$5.34M1.3%
Altimmune, Inc.1.74MUS$4.98M1.2%
JATT III Acquisition Corp450KUS$4.96M1.2%
Cullinan Therapeutics, Inc.300KUS$4.61M1.1%
Cybin, Inc.321KUS$3.94M0.94%
Rezolute, Inc.952KUS$3.94M0.94%
Opus Genetics, Inc.777KUS$3.76M0.90%
Enliven Therapeutics, Inc.70,000US$3.21M0.77%
Relmada Therapeutics, Inc.842KUS$3.17M0.76%
DBV Technologies SA250KUS$2.94M0.70%
Evommune, Inc.325KUS$2.68M0.64%
Contineum Therapeutics, Inc.186KUS$2.5M0.60%
Oruka Therapeutics, Inc.24,649US$2.05M0.49%
Humacyte, Inc.3.75MUS$1.94M0.46%
Rein Therapeutics, Inc.1.66MUS$1.34M0.32%
Research Alliance Corporation IV106KUS$1.28M0.31%
Alumis Inc.0US$00.00%
Immix Biopharma, Inc.0US$00.00%
Palisade Bio, Inc.0US$00.00%
ProMIS Neurosciences Inc.0US$00.00%

Source

Download original · View original at SEC

Related